Urate-lowering therapy for the prevention and treatment of gout flare

Jennifer A. Tilleman, Edward M. DeSimone, Richard McAuliffe

Research output: Contribution to specialist publicationArticle

Abstract

Gout is one of the most common rheumatologic arthritic diseases in the United States. Preventing future gout attacks requires lowering serum urate levels to promote dissolution of urate crystals, which is accomplished by reducing the production of serum uric acid or promoting its excretion. Xanthene oxidase inhibitors (XOIs), including allopurinol and febuxostat, are first-line agents for the prevention of acute attacks. Probenecid, a uricosuric agent, is an appropriate adjunctive therapy or second-line agent when XOIs are contraindicated or poorly tolerated. Recently, several third-line agents (e.g., pegloticase, lesinurad) have become available for the treatment of refractory gout.

Original languageEnglish (US)
Pages33-37
Number of pages5
Volume42
No3
Specialist publicationU.S. Pharmacist
StatePublished - Mar 1 2017

Fingerprint

Gout
Xanthenes
Uric Acid
Uricosuric Agents
Oxidoreductases
Probenecid
Allopurinol
Serum
Refractory materials
Arthritis
Dissolution
Therapeutics
Crystals

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmaceutical Science

Cite this

Urate-lowering therapy for the prevention and treatment of gout flare. / Tilleman, Jennifer A.; DeSimone, Edward M.; McAuliffe, Richard.

In: U.S. Pharmacist, Vol. 42, No. 3, 01.03.2017, p. 33-37.

Research output: Contribution to specialist publicationArticle

Tilleman, Jennifer A. ; DeSimone, Edward M. ; McAuliffe, Richard. / Urate-lowering therapy for the prevention and treatment of gout flare. In: U.S. Pharmacist. 2017 ; Vol. 42, No. 3. pp. 33-37.
@misc{ad679daaa82d40c98d8794834d2c8b10,
title = "Urate-lowering therapy for the prevention and treatment of gout flare",
abstract = "Gout is one of the most common rheumatologic arthritic diseases in the United States. Preventing future gout attacks requires lowering serum urate levels to promote dissolution of urate crystals, which is accomplished by reducing the production of serum uric acid or promoting its excretion. Xanthene oxidase inhibitors (XOIs), including allopurinol and febuxostat, are first-line agents for the prevention of acute attacks. Probenecid, a uricosuric agent, is an appropriate adjunctive therapy or second-line agent when XOIs are contraindicated or poorly tolerated. Recently, several third-line agents (e.g., pegloticase, lesinurad) have become available for the treatment of refractory gout.",
author = "Tilleman, {Jennifer A.} and DeSimone, {Edward M.} and Richard McAuliffe",
year = "2017",
month = "3",
day = "1",
language = "English (US)",
volume = "42",
pages = "33--37",
journal = "U.S. Pharmacist",
issn = "0148-4818",
publisher = "Jobson Publishing Corporation",

}

TY - GEN

T1 - Urate-lowering therapy for the prevention and treatment of gout flare

AU - Tilleman, Jennifer A.

AU - DeSimone, Edward M.

AU - McAuliffe, Richard

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Gout is one of the most common rheumatologic arthritic diseases in the United States. Preventing future gout attacks requires lowering serum urate levels to promote dissolution of urate crystals, which is accomplished by reducing the production of serum uric acid or promoting its excretion. Xanthene oxidase inhibitors (XOIs), including allopurinol and febuxostat, are first-line agents for the prevention of acute attacks. Probenecid, a uricosuric agent, is an appropriate adjunctive therapy or second-line agent when XOIs are contraindicated or poorly tolerated. Recently, several third-line agents (e.g., pegloticase, lesinurad) have become available for the treatment of refractory gout.

AB - Gout is one of the most common rheumatologic arthritic diseases in the United States. Preventing future gout attacks requires lowering serum urate levels to promote dissolution of urate crystals, which is accomplished by reducing the production of serum uric acid or promoting its excretion. Xanthene oxidase inhibitors (XOIs), including allopurinol and febuxostat, are first-line agents for the prevention of acute attacks. Probenecid, a uricosuric agent, is an appropriate adjunctive therapy or second-line agent when XOIs are contraindicated or poorly tolerated. Recently, several third-line agents (e.g., pegloticase, lesinurad) have become available for the treatment of refractory gout.

UR - http://www.scopus.com/inward/record.url?scp=85017537116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017537116&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 33

EP - 37

JO - U.S. Pharmacist

JF - U.S. Pharmacist

SN - 0148-4818

ER -